Group 1 - Avanos Medical, Inc. (NYSE: AVNS) is perceived as undervalued due to its expanding international presence and aggressive M&A strategy [1] - The company operates in growth target markets, particularly the neonatal enteral feeding devices market [1] - The analysis is based on cash flow statements and unlevered free cash flow figures, with a focus on historical financial data and future forecasts [1] Group 2 - The article emphasizes the importance of financial models that include various metrics such as cost of capital, cost of debt, WACC, share count, and net debt [1] - The author provides access to a database with over 15,000 DCF models ranked by margin of safety and upside potential [1]

Key Takeaways AVNS acquired Nexus Medical to expand its Specialty Nutrition Systems business.The deal adds TKO connector to AVNS' portfolio, reducing occlusions and infection risks in IV therapy.The acquisition is cash-funded and immediately accretive to AVNS revenues and EPS.Avanos Medical, Inc. (AVNS) recently announced that it has acquired Nexus Medical, LLC, a privately held device maker based in Lenexa, KS, to expand its footprint in critical care for nutrition and medication delivery. The move strengt ...

Key Takeaways Avanos Medical posted robust Q2 growth in SNS and solid RFA sales in Pain Management and Recovery.AVNS' transformation plan includes divestitures and acquisitions.Tariffs and FX volatility remain key risks, with $8M in Q2 costs and potential revenue pressure in 2025.Avanos Medical, Inc. (AVNS) is well-poised for growth in the coming quarters, courtesy of its impressive product line. The optimism, led by a decent fiscal second-quarter 2025 performance and continued robust product performance, i ...

Core Insights - Avanos Medical, Inc. reported a significant decline in adjusted earnings per share (EPS) for Q2 2025, with a 50% year-over-year drop to 17 cents, missing the Zacks Consensus Estimate by 5.6% [1][6] - The company's revenues increased by 1.9% year-over-year to $175 million, surpassing the Zacks Consensus Estimate by 4.7%, driven by strong demand in the Specialty Nutrition Systems (SNS) and radiofrequency ablation (RFA) segments [2][6] Revenue Analysis - Revenues for the SNS segment reached $102.7 million, up 5.1% year-over-year, with volume growth of 4.4% attributed to strong demand in enteral feeding and neonate solutions [9] - The Pain Management and Recovery (PM&R) segment reported revenues of $61 million, down 2.9% year-over-year, affected by unfavorable currency effects and strategic decisions to forgo certain revenue streams [7][8] - Corporate and Other segment revenues fell by 23.1% year-over-year to $11.3 million, primarily due to pricing pressures in the Hyaluronic Acid (HA) product lines [10] Margin and Profitability - Adjusted gross profit decreased by 4.7% year-over-year to $97.4 million, with the adjusted gross margin contracting by 390 basis points to 55.7% [12] - Selling and general expenses rose by 3.2% year-over-year to $83.5 million, while adjusted operating profit fell by 44% to $12.2 million, leading to an adjusted operating margin contraction of 580 basis points to 6.9% [12][13] Financial Position - At the end of Q2 2025, the company had cash and cash equivalents of $90.3 million, down from $97 million at the end of Q1 2025, with total debt slightly reduced to $105.1 million [14] - Cumulative net cash provided by operating activities increased to $32.5 million compared to $19.8 million in the prior-year period [14] Guidance and Outlook - Avanos has reiterated its 2025 outlook, estimating net sales between $665 million and $685 million, with a Zacks Consensus Estimate of $677.1 million [15] - The company anticipates adjusted EPS for 2025 to be between 75 and 95 cents, with the current consensus at 92 cents [15] Strategic Developments - In July, Avanos announced the divestiture of its HA product line to Channel-Markers Medical, aligning with its strategic focus on enhancing its PM&R and SNS segments [11] - The company is facing a volatile tariff environment, estimating an additional $15 million in manufacturing costs for 2025, primarily due to tariffs on products sourced from Mexico and China [18]

[PART I – FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company presents its unaudited condensed consolidated financial statements and related notes for the periods presented [Unaudited Condensed Consolidated Income Statements](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Income%20Statements) Condensed Consolidated Income Statement Highlights (in millions, except per share amounts) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Net Sales | $175.0 | $171.7 | $342.5 | $337.8 | | Gross Profit | $92.1 | $95.6 | $181.9 | $190.4 | | Goodwill impairment | $77.0 | — | $77.0 | — | | Operating (Loss) Income | $(74.5) | $6.3 | $(64.2) | $10.3 | | Net (Loss) Income | $(76.8) | $1.8 | $(70.2) | $0.9 | | Basic (Loss) Earnings Per Share | $(1.66) | $0.04 | $(1.52) | $0.02 | | Diluted (Loss) Earnings Per Share | $(1.66) | $0.04 | $(1.52) | $0.02 | [Unaudited Condensed Consolidated Statements of Comprehensive Income](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income) Condensed Consolidated Statements of Comprehensive Income (Loss) Highlights (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Net (Loss) Income | $(76.8) | $1.8 | $(70.2) | $0.9 | | Total Other Comprehensive Income (Loss) | $10.3 | $(8.0) | $12.6 | $(10.5) | | Comprehensive (Loss) Income | $(66.5) | $(6.2) | $(57.6) | $(9.6) | [Unaudited Condensed Consolidated Balance Sheets](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $90.3 | $107.7 | | Total Current Assets | $356.0 | $393.4 | | Goodwill | $381.2 | $455.6 | | TOTAL ASSETS | $1,039.0 | $1,154.2 | | Total Current Liabilities | $134.6 | $165.9 | | Long-Term Debt | $95.7 | $125.3 | | Total Liabilities | $262.7 | $325.7 | | Total Stockholders' Equity | $776.3 | $828.5 | | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $1,039.0 | $1,154.2 | [Unaudited Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Condensed Consolidated Statement of Stockholders' Equity Highlights (in millions) | Metric | June 30, 2025 (YTD) | June 30, 2024 (YTD) | | :--- | :--- | :--- | | Additional Paid-in Capital, end of period | $1,686.9 | $1,671.5 | | Accumulated Deficit, end of period | $(777.2) | $(314.0) | | Treasury Stock, end of period | $(101.9) | $(98.5) | | Accumulated Other Comprehensive Loss, end of period | $(32.0) | $(37.5) | | Total Stockholders' Equity, end of period | $776.3 | $1,222.0 | [Unaudited Condensed Consolidated Cash Flow Statements](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Cash%20Flow%20Statements) Condensed Consolidated Cash Flow Statement Highlights (in millions) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Cash Provided by Operating Activities | $32.5 | $19.8 | | Cash Used in Investing Activities | $(22.3) | $(7.9) | | Cash Used in Financing Activities | $(32.3) | $(5.7) | | Effect of Exchange Rate Changes on Cash | $4.7 | $(1.7) | | (Decrease) Increase in Cash and Cash Equivalents | $(17.4) | $4.5 | | Cash and Cash Equivalents - End of Period | $90.3 | $92.2 | [Notes to the Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) [Note 1. Accounting Policies](index=9&type=section&id=Note%201.%20Accounting%20Policies) - Avanos Medical, Inc is a medical technology company focused on clinically superior medical device solutions, addressing nutrition and pain management needs globally[20](index=20&type=chunk) - The interim financial statements are prepared in accordance with GAAP for interim information and Rule 10-01 of Regulation S-X, and should be read with the Annual Report on Form 10-K for the year ended December 31, 2024[21](index=21&type=chunk) - The company adopted ASU No 2023-05 (Joint Venture Formations) and ASU No 2023-07 (Segment Reporting) in 2025 and Q4 2024, respectively, with **no material effect** on financial position, results, or cash flows[28](index=28&type=chunk)[29](index=29&type=chunk) - FASB issued ASU No 2024-03 (Disaggregation of Income Statement Expenses) in November 2024, effective for annual periods after December 15, 2026, which is **not expected to materially affect** financial statements[30](index=30&type=chunk) [Note 2. Goodwill Impairment](index=10&type=section&id=Note%202.%20Goodwill%20Impairment) - In the second quarter of 2025, Avanos recorded a **$77.0 million goodwill impairment** related to its Pain Management and Recovery (PM&R) reporting unit due to a decrease in market capitalization[32](index=32&type=chunk) Changes in Goodwill Carrying Amount (in millions) | Segment | Balance, December 31, 2024 | Goodwill Impairment | Currency Translation Adjustment | Balance, June 30, 2025 | | :--- | :--- | :--- | :--- | :--- | | SNS | $327.6 | — | — | $327.6 | | PM&R | $128.0 | $(77.0) | $2.6 | $53.6 | | Total | $455.6 | $(77.0) | $2.6 | $381.2 | [Note 3. Segment Information](index=10&type=section&id=Note%203.%20Segment%20Information) - Effective Q1 2025, the company manages its business in two operating and reportable segments: **Specialty Nutrition Systems (SNS)** and **Pain Management and Recovery (PM&R)**[34](index=34&type=chunk)[35](index=35&type=chunk) - Corporate and other expenses for the six months ended June 30, 2025, include a **$77.0 million goodwill impairment** associated with the PM&R reporting unit[38](index=38&type=chunk) Segment Net Sales and Operating Income (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Sales:** | | | | | | SNS | $102.7 | $97.7 | $203.8 | $192.3 | | PM&R | $61.0 | $59.3 | $117.2 | $115.6 | | Total Segment Net Sales | $163.7 | $157.0 | $321.0 | $307.9 | | **Reportable Segment Operating Income (Loss):** | | | | | | SNS | $18.0 | $21.8 | $39.1 | $37.2 | | PM&R | $1.8 | $0.1 | $2.0 | $(2.0) | | Total Segment Operating Income (Loss) | $19.8 | $21.9 | $41.1 | $35.2 | [Note 4. Restructuring Activities](index=12&type=section&id=Note%204.%20Restructuring%20Activities) - The company initiated a three-year Transformation Process in January 2023, substantially complete by end of 2024, incurring **$27.4 million in net expenses** since inception[39](index=39&type=chunk)[40](index=40&type=chunk) - A Post-RH Divestiture Plan, initiated in 2024 and expanded in H1 2025, is expected to be substantially complete by end of 2025, with **$7.6 million in costs incurred in H1 2025**[41](index=41&type=chunk) - The restructuring liability as of June 30, 2025, was **$1.7 million**, down from $3.8 million at December 31, 2024[44](index=44&type=chunk) [Note 5. Supplemental Balance Sheet Information](index=13&type=section&id=Note%205.%20Supplemental%20Balance%20Sheet%20Information) Accounts Receivable (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Accounts receivable, net of allowances | $110.2 | $132.8 | Inventories (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Inventories | $142.7 | $138.8 | Property, Plant and Equipment, net (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Property, Plant and Equipment, net | $114.3 | $110.7 | Intangible Assets, net (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Net Carrying Amount | $105.4 | $112.3 | Accrued Expenses (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Accrued Expenses | $66.0 | $91.3 | [Note 6. Discontinued Operations](index=15&type=section&id=Note%206.%20Discontinued%20Operations) - The sale of the Respiratory Health (RH) business closed on October 2, 2023, for **$110 million cash**, with the final transfer of manufacturing assets completed on October 1, 2024[52](index=52&type=chunk)[53](index=53&type=chunk)[95](index=95&type=chunk) - **No activity from discontinued operations** was reported for the three and six months ended June 30, 2025[55](index=55&type=chunk)[102](index=102&type=chunk) Financial Results of Discontinued Operations (in millions) for 2024 | Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net Sales | $13.6 | $30.5 | | Net Loss from discontinued operations, net of tax | $(2.5) | $(3.9) | [Note 7. Fair Value Information](index=16&type=section&id=Note%207.%20Fair%20Value%20Information) - The company uses a three-level fair value hierarchy for financial instruments, with **Level 1** for quoted prices in active markets, **Level 2** for similar assets/liabilities or observable inputs, and **Level 3** for unobservable inputs[58](index=58&type=chunk)[59](index=59&type=chunk) Fair Value of Financial Instruments (in millions) | Instrument | Fair Value Hierarchy Level | June 30, 2025 Carrying Amount | June 30, 2025 Estimated Fair Value | December 31, 2024 Carrying Amount | December 31, 2024 Estimated Fair Value | | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and cash equivalents | 1 | $90.3 | $90.3 | $107.7 | $107.7 | | Revolving Credit Facility | 2 | — | — | $25.0 | $25.0 | | Term Loan Facility | 2 | $105.1 | $105.1 | $109.7 | $109.7 | [Note 8. Debt](index=17&type=section&id=Note%208.%20Debt) - The company entered into a **$500.0 million credit agreement** on June 24, 2022, consisting of a $125.0 million Term Loan Facility and a $375.0 million Revolving Credit Facility, maturing on June 24, 2027[62](index=62&type=chunk) - During the six months ended June 30, 2025, the company repaid **$4.7 million** of the Term Loan Facility and **$25.0 million** of the Revolving Credit Facility[66](index=66&type=chunk) Debt Balances (in millions) | Debt Type | Weighted-Average Interest Rate | Maturity | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | :--- | :--- | | Revolving Credit Facility | 5.94% | 2027 | $— | $25.0 | | Term Loan Facility | 5.82% | 2027 | $105.5 | $110.2 | | Total Long-Term Debt, net | | | $95.7 | $125.3 | [Note 9. Accumulated Other Comprehensive Loss](index=18&type=section&id=Note%209.%20Accumulated%20Other%20Comprehensive%20Loss) Changes in Accumulated Other Comprehensive Loss (AOCL) (in millions) | Component | Balance, December 31, 2024 | Other Comprehensive Income (Loss) | Balance, June 30, 2025 | | :--- | :--- | :--- | :--- | | Unrealized Currency Translation | $(44.9) | $11.4 | $(33.5) | | Cash Flow Hedges | — | $1.1 | $1.1 | | Defined Benefit Plans | $0.3 | $0.1 | $0.4 | | Total Accumulated Other Comprehensive Loss | $(44.6) | $12.6 | $(32.0) | [Note 10. Stock-Based Compensation](index=18&type=section&id=Note%2010.%20Stock-Based%20Compensation) Stock-Based Compensation Expense (in millions) | Type of Award | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Stock options | $0.2 | — | $0.2 | — | | Time-based restricted share units | $3.5 | $2.4 | $6.6 | $4.9 | | Performance-based restricted share units | $0.3 | $1.4 | $1.0 | $2.4 | | Employee stock purchase plan | $0.1 | — | $0.1 | $0.1 | | Total stock-based compensation | $4.1 | $3.8 | $7.9 | $7.4 | [Note 11. Commitments and Contingencies](index=18&type=section&id=Note%2011.%20Commitments%20and%20Contingencies) - The company is subject to various legal proceedings, claims, and governmental investigations, but believes the ultimate resolution will **not materially adversely affect** its business or financial condition[70](index=70&type=chunk)[75](index=75&type=chunk) - The DOJ's criminal investigation related to MicroCool surgical gowns was **dismissed in January 2025**, following the DPA term expiration in July 2024[71](index=71&type=chunk) - The company operates in an industry with **extensive patent litigation**, which can be costly and result in significant damage awards or injunctions[72](index=72&type=chunk) [Note 12. Derivative Financial Instruments](index=19&type=section&id=Note%2012.%20Derivative%20Financial%20Instruments) - The company uses derivative instruments, specifically foreign currency swap contracts, to hedge forecasted cash flows denominated in Mexican pesos, designated as cash flow hedges[77](index=77&type=chunk) - As of June 30, 2025, the derivative asset for foreign exchange contracts was **$1.4 million**, and the aggregate notional value of outstanding foreign currency swap contracts was **$21.6 million**[77](index=77&type=chunk)[78](index=78&type=chunk) [Note 13. Earnings Per Share ("EPS")](index=19&type=section&id=Note%2013.%20Earnings%20Per%20Share%20(%22EPS%22)) - For the three and six months ended June 30, 2025, **2.5 million and 1.8 million potentially dilutive stock options and RSU awards**, respectively, were excluded from EPS computation as they were anti-dilutive[81](index=81&type=chunk) Basic and Diluted EPS (in millions, except per share amounts) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Net (Loss) Income | $(76.8) | $1.8 | $(70.2) | $0.9 | | Basic (Loss) Earnings Per Share | $(1.66) | $0.04 | $(1.52) | $0.02 | | Diluted (Loss) Earnings Per Share | $(1.66) | $0.04 | $(1.52) | $0.02 | | Basic weighted average shares outstanding | 46.3 | 45.9 | 46.2 | 46.1 | | Diluted weighted average shares outstanding | 46.3 | 46.3 | 46.2 | 46.6 | [Note 14. Revenue](index=20&type=section&id=Note%2014.%20Revenue) Net Sales by Product Category (in millions) | Product Category | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | **Specialty Nutrition Systems:** | | | | | | Enteral feeding | $74.5 | $72.7 | $149.0 | $142.7 | | Neonate solutions | $28.2 | $25.0 | $54.8 | $49.6 | | Total SNS | $102.7 | $97.7 | $203.8 | $192.3 | | **Pain Management and Recovery:** | | | | | | Surgical pain and recovery | $25.2 | $27.8 | $49.7 | $54.8 | | Radiofrequency ablation | $35.8 | $31.5 | $67.5 | $60.8 | | Total PM&R | $61.0 | $59.3 | $117.2 | $115.6 | | Corporate and Other | $11.3 | $14.7 | $21.5 | $29.9 | | Total Net Sales | $175.0 | $171.7 | $342.5 | $337.8 | Liabilities for Estimated Returns, Rebates and Incentives (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Accrued rebates and customer incentives | $23.1 | $24.2 | | Accrued sales returns | $0.1 | $0.1 | | Total estimated liabilities | $23.2 | $24.3 | [Note 15. Share Repurchase Programs](index=21&type=section&id=Note%2015.%20Share%20Repurchase%20Programs) - The Board approved a new one-year program on November 1, 2024, to repurchase up to **$25.0 million** of common stock[86](index=86&type=chunk) - **No common stock repurchases** occurred in the six months ended June 30, 2025[87](index=87&type=chunk) Common Stock Repurchases (Six Months Ended June 30, 2024) | Period | Shares Repurchased | Aggregate Purchase Price (in millions) | Average Price per Share | | :--- | :--- | :--- | :--- | | First quarter of 2024 | 342,680 | $6.7 | $19.45 | | Second quarter of 2024 | 169,571 | $3.3 | $19.67 | [Note 16. Subsequent Events](index=22&type=section&id=Note%2016.%20Subsequent%20Events) - The One Big Beautiful Bill Act (OBBBA) was enacted on July 4, 2025, extending or making permanent certain tax provisions, with the company currently assessing its impact[89](index=89&type=chunk) - On July 31, 2025, the company sold substantially all assets of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC, aligning with its strategic focus on PM&R and SNS segments[90](index=90&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition, operational results, and key business factors for the periods presented [Introduction](index=23&type=section&id=Introduction) - Avanos is a medical technology company focused on delivering clinically superior medical device solutions for patient nutrition and pain management, holding leading market positions globally[91](index=91&type=chunk) [Goodwill Impairment](index=23&type=section&id=Goodwill%20Impairment) - A **$77.0 million goodwill impairment** was recorded in Q2 2025 for the Pain Management and Recovery reporting unit due to a decrease in market capitalization[93](index=93&type=chunk) [Divestiture of the Respiratory Health Business](index=23&type=section&id=Divestiture%20of%20the%20Respiratory%20Health%20Business) - The sale of the Respiratory Health (RH) business to SunMed Group Holdings, LLC, for **$110 million cash**, was finalized on October 1, 2024, with remaining transition services to terminate within three years[94](index=94&type=chunk)[95](index=95&type=chunk)[96](index=96&type=chunk) [Restructuring Activities](index=24&type=section&id=Restructuring%20Activities) - The three-year Transformation Process, initiated in January 2023, was largely complete by the end of 2024, focusing on commercial organization, portfolio rationalization, and cost management[98](index=98&type=chunk)[99](index=99&type=chunk) - The Post-RH Divestiture Plan, aimed at aligning organizational structure and operational footprint, incurred **$7.6 million in costs in H1 2025** and may expand through 2026 under the new CEO[100](index=100&type=chunk)[101](index=101&type=chunk) [Discontinued Operations](index=24&type=section&id=Discontinued%20Operations) - **No net sales from discontinued operations** were reported for the three and six months ended June 30, 2025, following the RH Divestiture[102](index=102&type=chunk) [Risks Related to Tariffs](index=24&type=section&id=Risks%20Related%20to%20Tariffs) - New and increased U.S tariffs and retaliatory measures pose **significant risks** to global operations, particularly due to manufacturing in Mexico and Canada, and sourcing from foreign suppliers[103](index=103&type=chunk) - The company has implemented mitigation strategies including cost containment, pricing actions, and supply chain adjustments, but inability to offset costs or reduced demand could **negatively impact financial performance**[103](index=103&type=chunk) [Results of Operations and Related Information](index=24&type=section&id=Results%20of%20Operations%20and%20Related%20Information) [Use of Non-GAAP Measures](index=24&type=section&id=Use%20of%20Non-GAAP%20Measures) - The company uses **'Adjusted operating income'** as a non-GAAP measure to assess operational performance and provide insight into ongoing business operations[104](index=104&type=chunk) [Net Sales](index=25&type=section&id=Net%20Sales) Net Sales by Segment (in millions) | Segment | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change (QoQ) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $102.7 | $97.7 | 5.1% | $203.8 | $192.3 | 6.0% | | Pain Management and Recovery | $61.0 | $59.3 | 2.9% | $117.2 | $115.6 | 1.4% | | Corporate and Other | $11.3 | $14.7 | (23.1)% | $21.5 | $29.9 | (28.1)% | | Total Net Sales | $175.0 | $171.7 | 1.9% | $342.5 | $337.8 | 1.4% | Net Sales - Percentage Change Breakdown (QTD) | Segment | Total | Volume | Pricing/Mix | Currency | (a) Other | | :--- | :--- | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | 5.1% | 4.4% | 0.5% | 0.7% | (0.5)% | | Pain Management and Recovery | 2.9% | 3.1% | 0.3% | 0.4% | (0.9)% | | Corporate and Other | (23.1)% | (26.4)% | (2.0)% | —% | 5.3% | [Net Sales by Segment - Second Quarter of 2025 Compared to the Second Quarter of 2024](index=25&type=section&id=Net%20Sales%20by%20Segment%20-%20Second%20Quarter%20of%202025%20Compared%20to%20the%20Second%20Quarter%20of%202024) - Specialty Nutrition Systems net sales **increased 5.1% to $102.7 million**, driven by 4.4% volume growth from strong demand in enteral feeding and neonate solutions[106](index=106&type=chunk) - Pain Management and Recovery net sales **increased 2.9% to $61.0 million**, with RFA solutions growing 13.7% due to generator sales, while surgical pain and recovery decreased 9.4% due to lower volume[108](index=108&type=chunk) [Net Sales by Segment - First Six Months of 2025 Compared to the First Six Months of 2024](index=26&type=section&id=Net%20Sales%20by%20Segment%20-%20First%20Six%20Months%20of%202025%20Compared%20to%20the%20First%20Six%20Months%20of%202024) - Specialty Nutrition Systems net sales **increased 6.0% to $203.8 million**, with 6.5% volume growth from continued strong demand[109](index=109&type=chunk) - Pain Management and Recovery net sales **increased 1.4% to $117.2 million**, with RFA solutions growing 11.0% from generator sales, offset by a 9.3% decrease in surgical pain and recovery due to lower volume[110](index=110&type=chunk) [Net Sales by Geographic Region](index=26&type=section&id=Net%20Sales%20by%20Geographic%20Region) Net Sales by Geographic Region (in millions) | Region | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change (QoQ) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | North America | $138.5 | $136.6 | 1.4% | $269.3 | $268.7 | 0.2% | | Europe, Middle East and Africa | $22.8 | $23.5 | (3.0)% | $46.5 | $46.5 | —% | | Asia Pacific and Latin America | $13.7 | $11.6 | 18.1% | $26.7 | $22.6 | 18.1% | | Total net sales | $175.0 | $171.7 | 1.9% | $342.5 | $337.8 | 1.4% | [Cost of Products Sold](index=26&type=section&id=Cost%20of%20Products%20Sold) - Cost of products sold increased in both the three and six months ended June 30, 2025, primarily due to **increased tariffs and higher net sales** across both reportable segments[113](index=113&type=chunk) Cost of Products Sold (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $46.9 | $39.8 | $90.3 | $80.0 | | Pain Management and Recovery | $26.9 | $24.9 | $51.8 | $48.9 | | Total Cost of Products Sold | $82.9 | $76.1 | $160.6 | $147.4 | [Research and Development](index=27&type=section&id=Research%20and%20Development) Research and Development Expenses (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $4.5 | $4.1 | $8.7 | $8.3 | | Pain Management and Recovery | $1.2 | $2.0 | $2.4 | $4.0 | | Total Research and Development | $5.8 | $6.3 | $11.2 | $13.3 | [Selling and General Expenses](index=27&type=section&id=Selling%20and%20General%20Expenses) - Selling and general expenses increased in Q2 2025 due to post-divestiture restructuring costs, but **decreased in H1 2025** due to savings from the Transformation Process and increased spending discipline[117](index=117&type=chunk) Selling and General Expenses (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $33.5 | $32.2 | $65.8 | $67.0 | | Pain Management and Recovery | $31.2 | $32.0 | $61.1 | $64.4 | | Total Selling and General Expenses | $83.5 | $80.9 | $159.2 | $164.5 | [Other (Income) Expense, net](index=27&type=section&id=Other%20(Income)%20Expense,%20net) - Other income in H1 2025 primarily relates to a **$1.4 million recovery** from a customer claim in 2023[118](index=118&type=chunk) Other (Income) Expense, net (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Other (Income) Expense, net | $0.3 | $2.1 | $(1.3) | $2.3 | [Operating Income (Loss)](index=28&type=section&id=Operating%20Income%20(Loss)) - Consolidated operating loss for Q2 and H1 2025 was primarily driven by the **$77.0 million goodwill impairment**[120](index=120&type=chunk) Operating Income (Loss) (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $18.0 | $21.8 | $39.1 | $37.2 | | Pain Management and Recovery | $1.8 | $0.1 | $2.0 | $(2.0) | | Total Operating Income (Loss) | $(74.5) | $6.3 | $(64.2) | $10.3 | [Adjusted Operating Income](index=28&type=section&id=Adjusted%20Operating%20Income) - Adjustments include post-RH Divestiture restructuring charges of **$4.5 million (Q2 2025)** and **$7.6 million (H1 2025)**, and a **$1.4 million recovery** for litigation and legal in H1 2025[123](index=123&type=chunk)[126](index=126&type=chunk) Adjusted Operating Income (Loss) (non-GAAP, in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Operating income (Loss), as reported (GAAP) | $(74.5) | $6.3 | $(64.2) | $10.3 | | Goodwill impairment | $77.0 | — | $77.0 | — | | Intangibles amortization | $5.2 | $6.3 | $10.3 | $12.4 | | Adjusted operating income (Loss) (non-GAAP) | $12.2 | $21.8 | $29.3 | $38.1 | [Interest Expense](index=29&type=section&id=Interest%20Expense) - Interest expense decreased due to **lower outstanding debt balances**, which were $105.1 million as of June 30, 2025, compared to $134.7 million as of December 31, 2024[128](index=128&type=chunk) Interest Expense (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Interest expense | $2.0 | $3.1 | $4.1 | $6.2 | [Income Taxes](index=29&type=section&id=Income%20Taxes) Income Tax Provision and Effective Tax Rate | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Income tax provision | $0.9 | $1.9 | $4.0 | $2.9 | | Effective tax rate | 1.2% | 30.6% | 6.0% | 37.7% | [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) - Primary liquidity sources are cash on hand from operating activities and the Revolving Credit Facility, expected to be **sufficient for working capital and capital expenditures** for the next twelve months[130](index=130&type=chunk) - Cash and cash equivalents **decreased by $17.4 million to $90.3 million** as of June 30, 2025, primarily due to debt repayments and capital expenditures, partially offset by operating cash flow[132](index=132&type=chunk) - As of June 30, 2025, **$51.7 million of the $90.3 million cash** and cash equivalents was held by foreign subsidiaries, considered indefinitely reinvested[131](index=131&type=chunk) - The company was **in compliance with all customary operational and financial covenants** under its Credit Agreement as of June 30, 2025[137](index=137&type=chunk) [Critical Accounting Policies and Use of Estimates](index=30&type=section&id=Critical%20Accounting%20Policies%20and%20Use%20of%20Estimates) - **No significant changes** to critical accounting estimates were reported in the three and six months ended June 30, 2025, from those disclosed in the Form 10-K[139](index=139&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=30&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes to its market risk position from the prior annual report - **No material changes** regarding the company's market risk position from the information provided in Item 7A of the Form 10-K[140](index=140&type=chunk) [Item 4. Controls and Procedures](index=30&type=section&id=Item%204.%20Controls%20and%20Procedures) Management confirms the effectiveness of disclosure controls and reports no material changes in internal controls - The CEO and CFO concluded that disclosure controls and procedures were **operating effectively** as of June 30, 2025[141](index=141&type=chunk) - **No changes in internal control over financial reporting** occurred during the three months ended June 30, 2025, that materially affected or are reasonably likely to materially affect internal control over financial reporting[142](index=142&type=chunk) [PART II – OTHER INFORMATION](index=31&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) The company discloses various legal proceedings that are not expected to have a material adverse effect - The company is subject to various legal proceedings, claims, and governmental investigations, but believes their ultimate resolution will **not materially adversely affect** its business, financial condition, results of operations, or liquidity[143](index=143&type=chunk) [Item 1A. Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) The company updates its risk factors, highlighting risks from new tariffs and international trade measures - The imposition of new and increased U.S tariffs and retaliatory trade measures by other countries poses **significant risks** to the company's global operations, particularly given its manufacturing in Mexico and Canada and sourcing from foreign suppliers[144](index=144&type=chunk)[145](index=145&type=chunk) - Inability to successfully pass through additional tariff costs, reduced demand due to higher prices, or failure to mitigate tariff impacts through supply chain adjustments could **materially negatively affect financial performance**[145](index=145&type=chunk) - Changes to international trade agreements like USMCA or WTO could result in **additional tariffs or trade restrictions**, further impacting the company's business[146](index=146&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=31&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section indicates no applicable information regarding unregistered sales of equity securities for the period - Not applicable[150](index=150&type=chunk) [Item 3. Defaults Upon Senior Securities](index=31&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section indicates no defaults upon senior securities to report for the period - Not applicable[150](index=150&type=chunk) [Item 4. Mine Safety Disclosures](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section states that mine safety disclosures are not applicable to the company - Not applicable[151](index=151&type=chunk) [Item 5. Other Information](index=32&type=section&id=Item%205.%20Other%20Information) This section indicates no other information to report for the period - None[151](index=151&type=chunk) [Item 6. Exhibits](index=33&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including corporate documents and certifications - The report includes various exhibits such as the Second Amended and Restated Certificate of Incorporation, Sixth Amended and Restated Bylaws, Section 302 CEO and CFO Certifications, Section 906 CEO and CFO Certifications, and XBRL Instance Document and Taxonomy Extension Documents[152](index=152&type=chunk) [Signatures](index=34&type=section&id=Signatures) This section contains the certifying signatures of the company's senior financial officers - The report is signed by Scott M Galovan, Senior Vice President, Chief Financial Officer, and John J Hurley, Controller, on August 5, 2025[155](index=155&type=chunk)

Financial Data and Key Metrics Changes - The company achieved net sales of $175 million for the quarter, with organic sales up 2% compared to the previous year [10] - Adjusted diluted earnings per share were $0.17, and adjusted EBITDA was $17 million, with adjusted gross margins at 55.7% and SG&A as a percentage of revenue at 45.2% [10] - A non-cash impairment charge of $77 million was recorded in the pain management and recovery reporting unit due to goodwill assessment [10] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems segment grew 5% organically, reaffirming its number one position in internal feeding [12] - The short-term internal feeding portfolio experienced double-digit growth globally, driven by the U.S. CoreTrack offering [13] - The pain management and recovery segment saw normalized organic sales up 3.4%, with the radiofrequency ablation (RFA) business growing nearly 14% [14][15] Market Data and Key Metrics Changes - The neonatal solutions business grew over 12% compared to the prior year [13] - The hyaluronic acid injections and intravenous infusion product lines reported a decline of over 20% due to pricing pressure [18] Company Strategy and Development Direction - The company closed the sale of its hyaluronic acid product line, focusing on growth in Specialty Nutrition Systems and Pain Management and Recovery segments [9] - The management is optimistic about improving commercial effectiveness through organizational enhancements and strategic partnerships [8] - The company aims to exit from China-sourced NeoMed products by 2026 as part of its supply chain strategy [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2025 financial guidance despite challenges from tariffs and market conditions [10][22] - The company anticipates approximately $15 million in incremental tariff-related manufacturing costs for the year [21] - Management noted that currency conditions have improved, and strategic segment growth remains healthy [22] Other Important Information - The company maintains a strong balance sheet with $90 million in cash and $105 million in debt as of June 30 [18] - Free cash flow for the quarter was negative approximately $4 million, but the company anticipates generating about $40 million of free cash flow for the year [19] Q&A Session Summary Question: 2025 guidance and its implications for SNS and pain management - Management reaffirmed full-year guidance, noting strong performance in Specialty Nutrition Systems and Pain Management segments [26][27] Question: Growth sustainability in the RF ablation business - Management highlighted strong momentum in the RF ablation segment, driven by a dedicated focus and a three-tiered offering [30][31] Question: Long-term impact of divestiture on income statement - Management indicated that the divestiture would not have a material impact on the bottom line, as strong performance in strategic segments would offset any losses [39][40]

Financial Performance - Q2 2025 - Net sales reached $175 million, a 2% organic growth compared to $172 million in Q2 2024[17] - Adjusted EBITDA was $17 million, representing a 10% margin, compared to $27 million in Q2 2024[17] - Adjusted EPS was $0.17, compared to $0.34 in Q2 2024[17] Segment Performance - Specialty Nutrition Systems net sales grew to $103 million, a 5% organic growth, compared to $98 million in Q2 2024[20] - Specialty Nutrition Systems operating profit was $18 million, representing an 18% margin, compared to $22 million in Q2 2024[21] - Pain Management & Recovery net sales grew to $61 million, a 34% organic growth, compared to $59 million in Q2 2024[26] - Pain Management & Recovery operating profit increased to $2 million, compared to $0 million in Q2 2024[27] Financial Position - Cash decreased to $90 million as of June 30, 2025, compared to $108 million as of December 31, 2024[30] - Net debt decreased to $15 million as of June 30, 2025, compared to $27 million as of December 31, 2024[30] - Net Debt / EBITDA ratio was approximately 02x as of June 30, 2025, compared to approximately 03x as of December 31, 2024[30] 2025 Outlook - Sales guidance reaffirmed at $665 million to $685 million[33] - Adjusted diluted EPS estimate maintained at $075 to $095[33]

Company Performance - Avanos Medical reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share, and down from $0.34 per share a year ago, representing an earnings surprise of -5.56% [1] - The company posted revenues of $175 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.70%, compared to year-ago revenues of $171.7 million [2] - Over the last four quarters, Avanos Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Avanos Medical shares have lost about 29.3% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current status translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.19 on revenues of $166.35 million, and for the current fiscal year, it is $0.92 on revenues of $677.14 million [7] - The outlook for the industry can materially impact the stock's performance, with the Medical - Instruments industry currently in the bottom 37% of Zacks industries [8]

[Executive Summary](index=1&type=section&id=Executive%20Summary) Avanos Medical, Inc. reported Q2 2025 financial results, with strong SNS performance and progress in PM&R, despite a significant net loss due to goodwill impairment, while maintaining 2025 guidance [Introduction and CEO Commentary](index=1&type=section&id=Introduction%20and%20CEO%20Commentary) Avanos Medical, Inc. reported its second quarter 2025 financial results, with CEO David Pacitti highlighting strong performance in the Specialty Nutrition Systems (SNS) segment and continued progress in the Pain Management & Recovery (PM&R) segment, expressing confidence in achieving the company's 2025 financial guidance - CEO David Pacitti noted strong Q2 performance, driven by healthy results in Specialty Nutrition Systems and progress in Pain Management & Recovery, expressing confidence in achieving 2025 financial guidance[3](index=3&type=chunk) [Second Quarter 2025 Financial Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) The second quarter of 2025 saw a modest 1.9% increase in net sales to $175.0 million, but reported a significant net loss of $76.8 million, primarily due to a goodwill impairment charge. Adjusted net income and adjusted diluted EPS both decreased by 50% year-over-year Second Quarter 2025 Key Financial Highlights | Metric | Q2 2025 (Millions USD) | Q2 2024 (Millions USD) | Change (%) | | :-------------------------------- | :--------------------- | :--------------------- | :--------- | | Total Net Sales | $175.0 | $171.7 | +1.9% | | Net Loss (Income) | $(76.8) | $4.3 (Income) | N.M. | | Adjusted Net Income | $7.9 | $15.8 | -50.0% | | Diluted Loss (Earnings) Per Share | $(1.66) | $0.09 (Earnings) | N.M. | | Adjusted Diluted Earnings Per Share | $0.17 | $0.34 | -50.0% | | Adjusted EBITDA | $17.0 | $26.8 | -36.6% | [Operating Results Overview](index=1&type=section&id=Operating%20Results%20Overview) This section details Avanos Medical's financial performance for Q2 and the first six months of 2025, highlighting net sales growth, gross margin decline, and significant operating losses due to a goodwill impairment charge [Second Quarter 2025 Performance](index=1&type=section&id=Second%20Quarter%202025%20Performance) Net sales for Q2 2025 increased by 1.9% to $175.0 million, driven by strong demand in Specialty Nutrition Systems and radiofrequency ablation (RFA) generator sales. However, gross margin declined to 52.6% (adjusted 55.7%) due to higher tariffs and lower HA product pricing. The company reported an operating loss of $74.5 million, primarily due to a $77.0 million goodwill impairment charge Q2 2025 Operating Results Summary | Metric | Q2 2025 (Millions USD) | Q2 2024 (Millions USD) | Change (%) | | :-------------------------------- | :--------------------- | :--------------------- | :--------- | | Net Sales | $175.0 | $171.7 | +1.9% | | Gross Margin | 52.6% | 55.7% | -3.1 pp | | Adjusted Gross Margin | 55.7% | 59.6% | -3.9 pp | | Selling & General Expenses (% of Net Sales) | 47.7% | 47.1% | +0.6 pp | | Adjusted SG&A (% of Net Sales) | 45.2% | 43.0% | +2.2 pp | | Operating Income (Loss) | $(74.5) | $6.3 (Profit) | N.M. | | Adjusted Operating Profit | $12.2 | $21.8 | -44.0% | - Gross profit margin decreased primarily due to the effects of **higher tariffs** and **lower pricing for hyaluronic acid (HA) products**[6](index=6&type=chunk) - Operating loss was primarily due to a **$77.0 million goodwill impairment charge**[8](index=8&type=chunk) [First Six Months of 2025 Performance](index=2&type=section&id=First%20Six%20Months%20of%202025%20Performance) For the first six months of 2025, net sales increased by 1.4% to $342.5 million, driven by volume growth in the SNS portfolio and RFA solutions. Gross margin declined to 53.1% (adjusted 56.2%) due to tariffs and HA product pricing. The company reported an operating loss of $64.2 million, including the $77.0 million goodwill impairment charge, leading to a net loss of $70.2 million First Six Months 2025 Operating Results Summary | Metric | 6 Months 2025 (Millions USD) | 6 Months 2024 (Millions USD) | Change (%) | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------- | | Net Sales | $342.5 | $337.8 | +1.4% | | Gross Margin | 53.1% | 56.4% | -3.3 pp | | Adjusted Gross Margin | 56.2% | 59.7% | -3.5 pp | | Selling & General Expenses (% of Net Sales) | 46.5% | 48.7% | -2.2 pp | | Adjusted SG&A (% of Net Sales) | 44.3% | 44.3% | 0.0 pp | | Operating Income (Loss) | $(64.2) | $10.3 (Profit) | N.M. | | Adjusted Operating Income | $29.3 | $38.1 | -23.1% | | Net Loss (Income) | $(70.2) | $4.8 (Income) | N.M. | | Adjusted Net Income | $19.9 | $25.9 | -23.2% | | Adjusted EBITDA | $38.6 | $48.4 | -20.2% | - Operating loss for the six months ended June 30, 2025, was **$64.2 million**, following a **$77.0 million impairment charge to goodwill**[11](index=11&type=chunk) [Segment Performance](index=2&type=section&id=Segment%20Performance) This section analyzes the performance of Avanos Medical's Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments for Q2 and the first six months of 2025, detailing sales growth and key drivers [Second Quarter 2025 Segment Results](index=2&type=section&id=Second%20Quarter%202025%20Segment%20Results) The Specialty Nutrition Systems (SNS) segment delivered above-market results with a 5.1% increase in net sales, driven by strong volume growth. The Pain Management & Recovery (PM&R) segment also saw net sales growth, primarily from a 13.7% increase in RFA products, which offset a decline in surgical pain and recovery sales Q2 2025 Segment Net Sales and Operating Income | Segment | Q2 2025 Net Sales (Millions USD) | Q2 2024 Net Sales (Millions USD) | Change (%) | Volume Growth (%) | Operating Income (Millions USD) | | :-------------------------------- | :------------------------------- | :------------------------------- | :--------- | :---------------- | :------------------------------ | | Specialty Nutrition Systems (SNS) | $102.7 | $97.7 | +5.1% | +4.4% | $18.0 | | Pain Management & Recovery (PM&R) | $61.0 | $59.3 | +2.9% | N/A | $1.8 | | - RFA Products | $35.8 | $31.5 | +13.7% | N/A | N/A | | - Surgical Pain & Recovery | $25.2 | $27.8 | -9.4% | N/A | N/A | - PM&R segment's volume growth was partially offset by the strategic decision not to pursue certain revenue streams[14](index=14&type=chunk) [First Six Months of 2025 Segment Results](index=3&type=section&id=First%20Six%20Months%20of%202025%20Segment%20Results) For the first six months of 2025, the SNS segment continued its strong performance with a 6.0% increase in net sales and 6.5% volume growth. The PM&R segment's net sales grew by 1.4%, driven by an 11.0% increase in RFA products, which helped to offset a 9.3% decline in surgical pain and recovery sales First Six Months 2025 Segment Net Sales and Operating Income | Segment | 6 Months 2025 Net Sales (Millions USD) | 6 Months 2024 Net Sales (Millions USD) | Change (%) | Volume Growth (%) | Operating Income (Loss) (Millions USD) | | :-------------------------------- | :----------------------------------- | :----------------------------------- | :--------- | :---------------- | :------------------------------------- | | Specialty Nutrition Systems (SNS) | $203.8 | $192.3 | +6.0% | +6.5% | $39.1 | | Pain Management & Recovery (PM&R) | $117.2 | $115.6 | +1.4% | N/A | $2.0 | | - RFA Products | $67.5 | $60.8 | +11.0% | N/A | N/A | | - Surgical Pain & Recovery | $49.7 | $54.8 | -9.3% | N/A | N/A | - PM&R segment's volume growth was partially offset by the strategic decision not to pursue certain revenue streams[16](index=16&type=chunk) [Strategic Developments and Financial Position](index=3&type=section&id=Strategic%20Developments%20and%20Financial%20Position) This section covers key strategic actions, including a significant goodwill impairment, changes in cash flow and debt, the divestiture of the HA product line, and the company's updated financial outlook for 2025 [Non-Cash Goodwill Impairment](index=3&type=section&id=Non-Cash%20Goodwill%20Impairment) During the second quarter, Avanos Medical recorded a non-cash goodwill impairment charge of $77.0 million within the Pain Management & Recovery (PM&R) segment, attributed to downward pressure on the company's market capitalization - A **$77.0 million goodwill impairment charge** was recorded in the PM&R segment due to downward pressure on market capitalization[17](index=17&type=chunk) [Cash Flow and Balance Sheet Summary](index=3&type=section&id=Cash%20Flow%20and%20Balance%20Sheet%20Summary) Cash on hand decreased to $90.3 million as of June 30, 2025, from $107.7 million at year-end 2024. Cash flow from operations for the six months improved to $32.5 million, while free cash flow for the same period was an inflow of $14.8 million. Total debt outstanding, net of unamortized discounts, decreased to $105.1 million Cash and Debt Overview | Metric | June 30, 2025 (Millions USD) | Dec 31, 2024 (Millions USD) | Change (Millions USD) | | :-------------------------- | :--------------------------- | :-------------------------- | :-------------------- | | Cash on Hand | $90.3 | $107.7 | $(17.4) | | Total Debt Outstanding (net) | $105.1 | $134.7 | $(29.6) | Cash Flow Summary | Metric | 6 Months 2025 (Millions USD) | 6 Months 2024 (Millions USD) | Change (Millions USD) | | :-------------------------- | :--------------------------- | :--------------------------- | :-------------------- | | Cash Flow from Operations | $32.5 | $19.8 | +$12.7 | | Free Cash Flow | $14.8 | $9.8 | +$5.0 | | Metric | Q2 2025 (Millions USD) | Q2 2024 (Millions USD) | Change (Millions USD) | | :-------------------------- | :--------------------- | :--------------------- | :-------------------- | | Free Cash Flow | $(4.2) | $21.9 | $(26.1) | [Sale of HA Product Line](index=3&type=section&id=Sale%20of%20HA%20Product%20Line) Avanos Medical announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC on July 31, 2025. This transaction is part of the company's ongoing transformation, focusing on advancing its strategic segments in Pain Management & Recovery (PM&R) and Specialty Nutrition Systems (SNS) - Divestiture of the HA product line to Channel-Markers Medical, LLC was announced on **July 31, 2025**, aligning with the strategic focus on PM&R and SNS segments[19](index=19&type=chunk) [2025 Financial Outlook](index=3&type=section&id=2025%20Financial%20Outlook) Avanos Medical maintained its 2025 estimated revenue guidance of $665 million to $685 million and adjusted diluted earnings per share (EPS) guidance of $0.75 to $0.95, which includes the impact of the HA divestiture. The outlook assumes successful mitigation of tariff impacts through various management plans 2025 Estimated Financial Outlook | Metric | 2025 Estimated Range | | :-------------------------------- | :------------------- | | Estimated Revenue | $665 million to $685 million | | Estimated Adjusted Diluted EPS | $0.75 to $0.95 | - The guidance on adjusted diluted earnings per share assumes management's mitigation plans will moderate the impact of tariffs through cost containment, pricing actions, supply chain adjustments, and reliance on existing international agreements[21](index=21&type=chunk) [Non-GAAP Financial Measures](index=4&type=section&id=Non-GAAP%20Financial%20Measures) This section explains the definition, purpose, and limitations of Avanos Medical's non-GAAP financial measures, along with a list of specific measures and the adjustments made to derive them [Definition, Purpose, and Limitations](index=4&type=section&id=Definition%2C%20Purpose%2C%20and%20Limitations) Avanos Medical provides non-GAAP financial measures as supplemental information, used by management and the board to evaluate performance, allocate resources, and measure operational performance, including for incentive compensation goals. The company acknowledges these measures have limitations and should not be considered in isolation from GAAP results - Non-GAAP financial measures are provided as supplemental information, used by management and the board to evaluate historical and prospective financial performance, allocate resources, and measure operational performance[23](index=23&type=chunk) - The compensation committee uses certain non-GAAP financial measures when setting and assessing achievement of incentive compensation goals[24](index=24&type=chunk) - Non-GAAP measures are supplemental and should not be considered in isolation or as an alternative to GAAP financial statement data, as they have limitations as analytical tools[25](index=25&type=chunk) [List of Measures and Adjustments](index=4&type=section&id=List%20of%20Measures%20and%20Adjustments) The non-GAAP financial measures include adjusted gross and operating income, adjusted net income, adjusted diluted EPS, adjusted EBITDA, and free cash flow. These measures exclude specific items such as acquisition and integration charges, restructuring and transformation activities, EU MDR compliance expenses, amortization of intangible assets, impairments of intangibles or goodwill, tax effects of adjusting items, and currency exchange rate changes - The non-GAAP financial measures include: **Adjusted gross and operating income**, **Adjusted income before taxes**, **Adjusted effective tax rate**, **Adjusted net income**, **Adjusted diluted earnings per share**, **Adjusted selling, general and administrative expenses**, **Adjusted EBITDA**, and **Free cash flow**[26](index=26&type=chunk) - These non-GAAP measures exclude items such as: acquisition and integration charges; restructuring and transformation activities; EU Medical Device Regulation (MDR) compliance expenses; amortization of intangible assets; impairments of intangibles or goodwill; tax effects of certain adjusting items; and the effects of changes in currency exchange rates[26](index=26&type=chunk) [Corporate Information](index=5&type=section&id=Corporate%20Information) This section provides details on Avanos Medical's conference call, an overview of the company, and a disclaimer regarding forward-looking statements and associated risks [Conference Call Details](index=5&type=section&id=Conference%20Call%20Details) Avanos Medical hosted a conference call and webcast on August 5, 2025, at 9 a.m. ET to discuss the results, with replay information provided for those unable to attend live - A conference call and webcast were hosted on **August 5, 2025, at 9 a.m. ET**, with replay details available for one week[28](index=28&type=chunk) [About Avanos Medical, Inc.](index=5&type=section&id=About%20Avanos%20Medical%2C%20Inc.) Avanos Medical (NYSE: AVNS) is a medical technology company headquartered in Alpharetta, Georgia, focused on delivering clinically superior solutions for patient nutrition (from hospital to home) and opioid-sparing pain management. The company develops, manufactures, and markets recognized brands globally, holding leading market positions in various categories - Avanos Medical is a medical technology company focused on delivering clinically superior solutions for patient nutrition and reducing opioid use in pain management[29](index=29&type=chunk) - The company develops, manufactures, and markets recognized brands globally, holding leading market positions in multiple categories[29](index=29&type=chunk) [Forward-Looking Statements Disclaimer](index=5&type=section&id=Forward-Looking%20Statements%20Disclaimer) This section serves as a cautionary statement, indicating that the press release contains forward-looking statements subject to various risks and uncertainties. These factors, including economic conditions, pricing pressures, supply chain disruptions, and regulatory actions, could cause actual results to differ materially from those expressed or implied - Forward-looking statements are based on current plans and expectations and are subject to various risks and uncertainties that could cause actual results to differ materially[30](index=30&type=chunk) - Key risk factors include: weakening economic conditions, pricing pressures, supply chain disruptions, regional conflicts, ability to execute transformation initiatives, inflationary pressures, impact of tariffs, financial conditions affecting the banking system, changes in foreign exchange markets, legislative and regulatory actions, product liability claims, and changes in the competitive environment[30](index=30&type=chunk) [Detailed Financial Statements and Reconciliations](index=6&type=section&id=Detailed%20Financial%20Statements%20and%20Reconciliations) This section presents comprehensive unaudited condensed consolidated financial statements, including income statements, balance sheets, cash flow statements, segment data, and detailed reconciliations of GAAP to non-GAAP measures [Condensed Consolidated Income Statements](index=6&type=section&id=Condensed%20Consolidated%20Income%20Statements) This table provides a detailed breakdown of Avanos Medical's unaudited condensed consolidated income statements for the second quarter and first six months of 2025 and 2024 Condensed Consolidated Income Statements (Unaudited) | Metric (Millions USD, except per share) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :-------------------------------------- | :------ | :------ | :------------ | :------------ | | Net Sales | $175.0 | $171.7 | $342.5 | $337.8 | | Cost of products sold | $82.9 | $76.1 | $160.6 | $147.4 | | Gross Profit | $92.1 | $95.6 | $181.9 | $190.4 | | Research and development expenses | $5.8 | $6.3 | $11.2 | $13.3 | | Selling and general expenses | $83.5 | $80.9 | $159.2 | $164.5 | | Goodwill impairment | $77.0 | $— | $77.0 | $— | | Operating Income (Loss) | $(74.5) | $6.3 | $(64.2) | $10.3 | | Income (Loss) Before Income Taxes | $(75.9) | $6.2 | $(66.2) | $7.7 | | Income (Loss) from Continuing Operations | $(76.8) | $4.3 | $(70.2) | $4.8 | | Net Income (Loss) | $(76.8) | $1.8 | $(70.2) | $0.9 | | Diluted Earnings (Loss) Per Share | $(1.66) | $0.04 | $(1.52) | $0.02 | [Discontinued Operations Summary](index=7&type=section&id=Discontinued%20Operations%20Summary) This table summarizes the financial results from discontinued operations for the second quarter and first six months of 2025 and 2024 Discontinued Operations Summary (Unaudited) | Metric (Millions USD, except per share) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :-------------------------------------- | :------ | :------ | :------------ | :------------ | | Net Sales | $— | $13.6 | $— | $30.5 | | Cost of products sold | $— | $15.6 | $— | $31.5 | | Gross Profit | $— | $(2.0) | $— | $(1.0) | | Loss from discontinued operations before income taxes | $— | $(3.4) | $— | $(5.3) | | Income tax benefit from discontinued operations | $— | $0.9 | $— | $1.4 | | Loss from discontinued operations, net of tax | $— | $(2.5) | $— | $(3.9) | | Diluted Loss Per Share | $— | $(0.05) | $— | $(0.08) | [Non-GAAP Reconciliations](index=8&type=section&id=Non-GAAP%20Reconciliations) This section provides detailed reconciliations of various non-GAAP financial measures to their most directly comparable GAAP financial measures for the three and six months ended June 30, 2025, and 2024 [Gross Profit Reconciliation](index=8&type=section&id=Gross%20Profit%20Reconciliation) This table reconciles reported GAAP gross profit and gross profit margin to adjusted non-GAAP figures for Q2 and the first six months of 2025 Gross Profit Reconciliation (Unaudited) | Metric (Millions USD) | Q2 2025 (As Reported) | Q2 2025 (As Adjusted) | 6 Months 2025 (As Reported) | 6 Months 2025 (As Adjusted) | | :-------------------- | :-------------------- | :-------------------- | :-------------------------- | :-------------------------- | | Gross Profit | $92.1 | $97.4 | $181.9 | $192.4 | | Gross profit margin, as reported | 52.6 % | N/A | 53.1 % | N/A | | Gross profit margin, as adjusted | N/A | 55.7 % | N/A | 56.2 % | [Operating Income (Loss) Reconciliation](index=9&type=section&id=Operating%20Income%20%28Loss%29%20Reconciliation) This table reconciles reported GAAP operating income (loss) to adjusted non-GAAP operating income for Q2 and the first six months of 2025 Operating Income (Loss) Reconciliation (Unaudited) | Metric (Millions USD) | Q2 2025 (As Reported) | Q2 2025 (As Adjusted) | 6 Months 2025 (As Reported) | 6 Months 2025 (As Adjusted) | | :-------------------- | :-------------------- | :-------------------- | :-------------------------- | :-------------------------- | | Operating Income (Loss) | $(74.5) | $12.2 | $(64.2) | $29.3 | [Income (Loss) Before Taxes Reconciliation](index=10&type=section&id=Income%20%28Loss%29%20Before%20Taxes%20Reconciliation) This table reconciles reported GAAP income (loss) before taxes to adjusted non-GAAP income before taxes for Q2 and the first six months of 2025 Income (Loss) Before Taxes Reconciliation (Unaudited) | Metric (Millions USD) | Q2 2025 (As Reported) | Q2 2025 (As Adjusted) | 6 Months 2025 (As Reported) | 6 Months 2025 (As Adjusted) | | :-------------------- | :-------------------- | :-------------------- | :-------------------------- | :-------------------------- | | Income (Loss) Before Taxes | $(75.9) | $10.8 | $(66.2) | $27.3 | [Tax (Provision) Benefit Reconciliation](index=11&type=section&id=Tax%20%28Provision%29%20Benefit%20Reconciliation) This table reconciles reported GAAP tax (provision) benefit and effective tax rate to adjusted non-GAAP figures for Q2 and the first six months of 2025 Tax (Provision) Benefit Reconciliation (Unaudited) | Metric | Q2 2025 (As Reported) | Q2 2025 (As Adjusted) | 6 Months 2025 (As Reported) | 6 Months 2025 (As Adjusted) | | :-------------------- | :-------------------- | :-------------------- | :-------------------------- | :-------------------------- | | Tax (Provision) Benefit | $(0.9) | $(2.9) | $(4.0) | $(7.4) | | Effective tax rate, as reported | (1.2)% | N/A | (6.0)% | N/A | | Effective tax rate, as adjusted | N/A | 26.9 % | N/A | 27.1 % | [Net Income (Loss) and Diluted EPS Reconciliation](index=12&type=section&id=Net%20Income%20%28Loss%29%20and%20Diluted%20EPS%20Reconciliation) This table reconciles reported GAAP net income (loss) and diluted EPS to adjusted non-GAAP figures for Q2 and the first six months of 2025 Net Income (Loss) and Diluted EPS Reconciliation (Unaudited) | Metric (Millions USD, except per share) | Q2 2025 (As Reported) | Q2 2025 (As Adjusted) | 6 Months 2025 (As Reported) | 6 Months 2025 (As Adjusted) | | :-------------------------------------- | :-------------------- | :-------------------- | :-------------------------- | :-------------------------- | | Net Income (Loss) | $(76.8) | $7.9 | $(70.2) | $19.9 | | Diluted earnings (loss) per share, as reported | $(1.66) | N/A | $(1.52) | N/A | | Diluted earnings (loss) per share, as adjusted | N/A | $0.17 | N/A | $0.43 | [Selling, General and Administrative Expenses Reconciliation](index=13&type=section&id=Selling%2C%20General%20and%20Administrative%20Expenses%20Reconciliation) This table reconciles reported GAAP selling, general and administrative expenses to adjusted non-GAAP figures for Q2 and the first six months of 2025 Selling, General and Administrative Expenses Reconciliation (Unaudited) | Metric (Millions USD) | Q2 2025 (As Reported) | Q2 2025 (As Adjusted) | 6 Months 2025 (As Reported) | 6 Months 2025 (As Adjusted) | | :-------------------- | :-------------------- | :-------------------- | :-------------------------- | :-------------------------- | | As reported | $83.5 | N/A | $159.2 | N/A | | As adjusted non-GAAP | N/A | $79.1 | N/A | $151.8 | | SG&A as a percentage of revenue, as reported | 47.7 % | N/A | 46.5 % | N/A | | SG&A as a percentage of revenue, as adjusted | N/A | 45.2 % | N/A | 44.3 % | [EBITDA Reconciliation](index=14&type=section&id=EBITDA%20Reconciliation) This table reconciles reported GAAP EBITDA to adjusted non-GAAP EBITDA for Q2 and the first six months of 2025 EBITDA Reconciliation (Unaudited) | Metric (Millions USD) | Q2 2025 (EBITDA) | Q2 2025 (Adjusted EBITDA) | 6 Months 2025 (EBITDA) | 6 Months 2025 (Adjusted EBITDA) | | :-------------------- | :--------------- | :------------------------ | :--------------------- | :------------------------------ | | EBITDA | $(64.5) | N/A | $(44.6) | N/A | | Adjusted EBITDA | N/A | $17.0 | N/A | $38.6 | [Free Cash Flow Reconciliation](index=15&type=section&id=Free%20Cash%20Flow%20Reconciliation) This table reconciles cash provided by operating activities to free cash flow for Q2 and the first six months of 2025 and 2024 Free Cash Flow Reconciliation (Unaudited) | Metric (Millions USD) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :-------------------- | :------ | :------ | :------------ | :------------ | | Cash provided by operating activities | $6.8 | $27.8 | $32.5 | $19.8 | | Capital expenditures | $(11.0) | $(5.9) | $(17.7) | $(10.0) | | Free Cash Flow | $(4.2) | $21.9 | $14.8 | $9.8 | [2025 Outlook Reconciliation Table](index=15&type=section&id=2025%20Outlook%20Reconciliation%20Table) This table provides a reconciliation of the 2025 estimated GAAP diluted earnings per share to the non-GAAP adjusted diluted earnings per share outlook 2025 Outlook: GAAP to Non-GAAP Diluted EPS Reconciliation | Metric | Estimated Range | | :-------------------------------- | :------------------- | | Diluted earnings per share (GAAP) | $0.33 to $0.56 | | Intangibles amortization | $0.25 to $0.24 | | Post RH-Divestiture restructuring charges | $0.12 to $0.10 | | Other | $0.05 to $0.05 | | Adjusted diluted earnings per share (non-GAAP) | $0.75 to $0.95 | [Condensed Consolidated Balance Sheets](index=16&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This table presents the unaudited condensed consolidated balance sheets as of June 30, 2025, and December 31, 2024, detailing assets, liabilities, and stockholders' equity Condensed Consolidated Balance Sheets (Unaudited) | Metric (Millions USD) | June 30, 2025 | December 31, 2024 | Change (Millions USD) | | :-------------------------- | :------------ | :---------------- | :-------------------- | | Cash and cash equivalents | $90.3 | $107.7 | $(17.4) | | Accounts receivable, net | $110.2 | $132.8 | $(22.6) | | Inventories | $142.7 | $138.8 | +$3.9 | | Total Current Assets | $356.0 | $393.4 | $(37.4) | | Property, Plant and Equipment, net | $114.3 | $110.7 | +$3.6 | | Goodwill | $381.2 | $455.6 | $(74.4) | | Other Intangible Assets, net | $105.4 | $112.3 | $(6.9) | | TOTAL ASSETS | $1,039.0 | $1,154.2 | $(115.2) | | Current portion of long-term debt | $9.4 | $9.4 | $0.0 | | Trade accounts payable | $48.8 | $54.3 | $(5.5) | | Accrued expenses | $66.0 | $91.3 | $(25.3) | | Total Current Liabilities | $134.6 | $165.9 | $(31.3) | | Long-Term Debt | $95.7 | $125.3 | $(29.6) | | TOTAL LIABILITIES | $262.7 | $325.7 | $(63.0) | | Stockholders' Equity | $776.3 | $828.5 | $(52.2) | | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $1,039.0 | $1,154.2 | $(115.2) | [Condensed Consolidated Cash Flow Statements](index=17&type=section&id=Condensed%20Consolidated%20Cash%20Flow%20Statements) This table outlines the unaudited condensed consolidated cash flow statements for the second quarter and first six months of 2025 and 2024, detailing operating, investing, and financing activities Condensed Consolidated Cash Flow Statements (Unaudited) | Cash Flow Activity (Millions USD) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :-------------------------------- | :------ | :------ | :------------ | :------------ | | Net income (loss) | $(76.8) | $1.8 | $(70.2) | $0.9 | | Depreciation and amortization | $10.0 | $11.3 | $19.6 | $22.7 | | Goodwill impairment | $77.0 | $— | $77.0 | $— | | Cash Provided by (Used in) Operating Activities | $6.8 | $27.8 | $32.5 | $19.8 | | Capital expenditures | $(11.0) | $(5.9) | $(17.7) | $(10.0) | | Cash Used in Investing Activities | $(13.2) | $(5.9) | $(22.3) | $(7.9) | | Secured debt repayments | $(2.4) | $(1.5) | $(4.7) | $(3.1) | | Revolving credit facility repayments | $— | $— | $(25.0) | $(10.0) | | Purchases of treasury stock | $(0.8) | $(3.5) | $(3.0) | $(12.6) | | Cash Used in Financing Activities | $(3.2) | $(5.0) | $(32.3) | $(5.7) | | Decrease (Increase) in Cash and Cash Equivalents | $(6.7) | $16.4 | $(17.4) | $4.5 | | Cash and Cash Equivalents - End of Period | $90.3 | $92.2 | $90.3 | $92.2 | [Selected Business Segment Data](index=18&type=section&id=Selected%20Business%20Segment%20Data) This section provides unaudited selected business segment data, including net sales and operating income (loss) for Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) for Q2 and the first six months of 2025 and 2024 Selected Business Segment Net Sales (Unaudited) | Segment (Millions USD) | Q2 2025 Net Sales | Q2 2024 Net Sales | Q2 Change (%) | 6 Months 2025 Net Sales | 6 Months 2024 Net Sales | 6 Months Change (%) | | :-------------------------------- | :------------------ | :------------------ | :------------ | :---------------------- | :---------------------- | :------------------ | | Specialty Nutrition Systems (SNS) | $102.7 | $97.7 | 5.1% | $203.8 | $192.3 | 6.0% | | Pain Management & Recovery (PM&R) | $61.0 | $59.3 | 2.9% | $117.2 | $115.6 | 1.4% | | - Surgical pain and recovery | $25.2 | $27.8 | (9.4)% | $49.7 | $54.8 | (9.3)% | | - Radiofrequency Ablation | $35.8 | $31.5 | 13.7% | $67.5 | $60.8 | 11.0% | | Corporate and Other | $11.3 | $14.7 | (23.1)% | $21.5 | $29.9 | (28.1)% | | Total Net Sales | $175.0 | $171.7 | 1.9% | $342.5 | $337.8 | 1.4% | Selected Business Segment Operating Income (Loss) (Unaudited) | Segment (Millions USD) | Q2 2025 Operating Income (Loss) | Q2 2024 Operating Income (Loss) | Q2 Change (%) | 6 Months 2025 Operating Income (Loss) | 6 Months 2024 Operating Income (Loss) | 6 Months Change (%) | | :-------------------------------- | :------------------------------ | :------------------------------ | :------------ | :------------------------------------ | :------------------------------------ | :------------------ | | Specialty Nutrition Systems (SNS) | $18.0 | $21.8 | (17.4)% | $39.1 | $37.2 | 5.1% | | Pain Management & Recovery (PM&R) | $1.8 | $0.1 | N.M. | $2.0 | $(2.0) | (200.0)% | | Corporate and Other | $(94.3) | $(15.6) | 504.5% | $(105.3) | $(24.9) | 322.9% | | Total Operating Income (Loss) | $(74.5) | $6.3 | N.M. | $(64.2) | $10.3 | N.M. | - Corporate and Other operating loss includes a **$77.0 million goodwill impairment** associated with the PM&R segment[59](index=59&type=chunk) - The 'Other' category in net sales percentage change includes the effects of withdrawal from certain revenue streams that did not meet return criteria[60](index=60&type=chunk)

Core Insights - Avanos Medical, Inc. has appointed Scott Galovan as the new senior vice president and chief financial officer, effective August 1, 2025 [1][3] - Galovan has a 12-year history with Avanos, previously serving as senior vice president of strategy and corporate development, and has extensive experience in M&A and finance roles [2][4] - The company aims to leverage Galovan's growth-oriented mindset to enhance long-term planning and shareholder value [4] Company Overview - Avanos Medical is a medical technology company focused on delivering clinically superior medical device solutions [5] - The company addresses critical healthcare needs, including providing nutrition support and reducing opioid use for patients transitioning from surgery to recovery [5] - Avanos holds leading market positions in multiple product categories and is headquartered in Alpharetta, Georgia [5]